We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Health Catalyst (HCAT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Health Catalyst (HCAT - Free Report) will announce quarterly earnings of $0.01 per share in its forthcoming report, representing no change year over year. Revenues are projected to reach $69.34 million, declining 12.7% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Health Catalyst metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenue- Professional services' should arrive at $19.93 million. The estimate suggests a change of -28.7% year over year.
The consensus among analysts is that 'Revenue- Technology' will reach $49.51 million. The estimate suggests a change of -3.8% year over year.
Analysts forecast 'Adjusted Gross Profit- Professional Services' to reach $3.34 million. The estimate is in contrast to the year-ago figure of $4.44 million.
Analysts expect 'Adjusted Gross Profit- Technology' to come in at $32.74 million. The estimate compares to the year-ago value of $34.61 million.
Over the past month, Health Catalyst shares have recorded returns of +52.4% versus the Zacks S&P 500 composite's +11.4% change. Based on its Zacks Rank #4 (Sell), HCAT will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Seeking Clues to Health Catalyst (HCAT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Analysts on Wall Street project that Health Catalyst (HCAT - Free Report) will announce quarterly earnings of $0.01 per share in its forthcoming report, representing no change year over year. Revenues are projected to reach $69.34 million, declining 12.7% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Health Catalyst metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenue- Professional services' should arrive at $19.93 million. The estimate suggests a change of -28.7% year over year.
The consensus among analysts is that 'Revenue- Technology' will reach $49.51 million. The estimate suggests a change of -3.8% year over year.
Analysts forecast 'Adjusted Gross Profit- Professional Services' to reach $3.34 million. The estimate is in contrast to the year-ago figure of $4.44 million.
Analysts expect 'Adjusted Gross Profit- Technology' to come in at $32.74 million. The estimate compares to the year-ago value of $34.61 million.
View all Key Company Metrics for Health Catalyst here>>>Over the past month, Health Catalyst shares have recorded returns of +52.4% versus the Zacks S&P 500 composite's +11.4% change. Based on its Zacks Rank #4 (Sell), HCAT will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .